You're getting 1/3 or shares free as an options, as soon as CR saga settles the SP appreciation will start as institutional entitlement is non-renounceable offer so they are not selling. The price target is $6.50 if successful after Phase 3 readouts for COAST (Combination OPT-302 with Aflibercept Study), and ShORe (Study of OPT-302 in combination with Ranibizumab),
The safety and superior efficacy of Sozinibercept is proven, than Sky is the limit after next readout
Ann: Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens, page-5
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 77447 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |